Arg-Gly-Asp (RGD) peptides and peptidomimetics as therapeutics: Relevance for renal diseases

Experimental Nephrology

Volumn 7, Issue 2, 1999, Pages 178-184

  Horton, Michael A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Integrin; Peptidomimetics; Platelet gpIIbIIIa; Renal diseases; RGD peptides; Vitronectin receptor (v) 3

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN;

ACUTE KIDNEY FAILURE; DRUG ACTIVITY; GLOMERULONEPHRITIS; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032951201     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020598     Document Type: Review

References (47)

1. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69: 11-25.
2. Barclay AN, Brown MH, Law ASK, McKnight AJ, Tomlinson MG, van der Merwe PA: The Leucocyte Antigen Facts Book, ed 2. San Diego, Harcourt Brace Jovanovich, 1997, p 613.
3. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 1995;268:233-239.
4. Hughes PE, Pfaff M: Integrin affinity modulation. Trends Cell Biol 1998;8:359-364.
5. Ruoslahti E: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
6. Pierchbacher MD; Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-33.
7. Gould RJ: The integrin αIIbβ3 as an antithrombotic target. Perspect Drug Discovery Design 1993;1:537-548.
8. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K: The pharmacology of the integrins. Med Res Rev 1994;14:195-228.
9. Gadek T, Blackburn BK: Identification and development of integrin/ligand antagonists for the treatment of human disease; Horton MA (ed): Adhesion Receptors as Therapeutic Targets. Boca Raton, CRC Press 1996, pp 247-272
10. Moran N: Novel antiplatelet drugs. Br J Cardiol 1998;5:413-423.
11. Theroux P: Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clincial cardiology: Issues and opportunities. Am Heart J 1998;135(suppl):107-112.
12. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 1996;78:35-40.
13. Coller BS: GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-735.
14. Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80:11-20.
15. Horton MA, Rodan GA: Integrins as therapeutic targets in bone disease; in Horton MA (ed): Adhesion Receptors as Therapeutic Targets. Boca Raton, CRC Press, 1996, pp 223-245.
16. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL: A peptidomimetic antagonist of the alpha(v) beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997;99:2284-2292.
17. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114: 1133-1142.
18. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H: Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J Am Chem Soc 1996;118:7461-7472.
19. Lazarus RA, McDowell RW: Structural and functional aspects of RGD-containing protein antagonists of glycoprotein IIb-IIIa. Curr Opin Biotechnol 1993;4:438-445.
20. Pasqualini R, Koivunen E, Ruoslahti E: A peptide isolated from phage display libraries is structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995;130: 1189-1196.
21. Corbett JW, Graciani NR, Mousa SA, De Grado WF: Solid-phase synthesis of a selective alpha(v)beta(3) integrin antagonist library. Bioorg Med Chem Lett 1997;7:1371-1376.
22. Kunicki TJ, Annis DS, Felding Habermann B: Molecular determinants of Arg-Gly-Asp ligand specifically for beta(3) integrins. J Biol Chem 1997;272:4103-4107.
23. Hoekstra WJ, Poulter BL: Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr Med Chem 1998;5: 194-204.
24. Lefkwoith JB, Simon EE: Adhesion receptors in renal development and disease; Horton MA (ed): Molecular Biology of Cell Adhesion Molecules. New York, Wiley & Sons, 1996, pp 155-174.
25. Simon EE, McDonald JA: Extracellular matrix receptors in the kidney cortex. Am J Physiol 1990;259:F783-F792.
26. Adler S: Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 1992; 141:571-578.
27. Cybulsky AV, Carbonetto S, Huang Q, McTavish AJ, Cyr MD: Adhesion of rat glomerular epithelial cells to extracellular matrices: Role of betal integrins. Kidney Int 1992;42:1099-1106.
28. Rahilly MA, Fleming S: Differential expression of integrin alpha chains by renal epithelial cells. J Pathol 1992;167:327-334.
29. Simon EE, Liu CH, Das M, Nigam S, Broekelmann TJ, McDonald JA: Characterization of integrins in cultured human renal cortical tubule epithelial cells. Am J Physiol 1994;267: F612-F623.
30. Goligorsky MS, DiBona GF: Pathogenetic role of Arg-Gly-Asp-recognizing integrins in acute renal failure. Proc Natl Acad Sci USA 1993;90: 5700-5704.
31. Noiri E, Gailit J, Sheth D, Magazine H, Gurrath M, Muller G, Kessler H, Goligorsky MS: Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int 1994;46: 1050-1058.
32. Goligorsky MS, Noiri E, Kessler H, Romanov V: Therapeutic effect of arginine-glycine-aspartic acid peptides and acute renal injury. Clin Exp Pharmacol Physiol 1998;25:276-279.
33. Taylor FB, Coller BS, Chang AC, Peer G, Jordan R, Engellener W, Esmon CT: 7E3 F(ab')s, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997;89:4078-4084.
34. Wu X, Helfrich MH, Horton MA, Feigen LP, Lefkowith JB: Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats. J Clin Invest 1994;94:928-936.
35. Mampaso F, Sanchez Madrid F, Marcen R, Molina A, Pascual J, Bricio T, Martin A, Alvarez V: Expression of adhesion molecules in allograft renal dysfunction: A distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation 1993;56:687-691.
36. Rabb H, Rosen R, Ramirez G: VLA-4 and its ligands: Relevance to kidney diseases. Springer Semin Immunopathol 1995;16:417-425.
37. Le Mauff B, Soulillon JP, Hourmant M: Clinical trials of adhesion receptor antagonists in renal transplantation; in Horton MA (ed): Adhesion Receptors as Therapeutic Targets. Boca Raton, CRC Press, 1996, pp 307-329.
38. Roy Chaudhury P, Hillis G, McDonald S, Simpson JG, Power DA: Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains beta 1, alpha 1 to 6 and alpha V. Kidney Int 1997;52: 103-110.
39. Shikata K, Makino H, Morioka S, Kashitani T, Hirata K, Ota Z, Wada J, Kanwar YS: Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 1995;25:680-688.
40. Patey N, Lesavre P, Halbwachs-Mecarelli L, Noel LH: Adhesion molecules in human crescentic glomerulonephritis. J Pathol 1996;179: 414-420.
41. Ogawa T, Yorioka N, Ito T, Ogata S, Kumagai J, Kawanishi H, Yamakido M: Precise ultrastructural localization of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in patients with IgA nephropathy. Nephron 1997;75:54-64.
42. Korhonen M, Laitinen L, Ylanne J, Koukoulis GK, Quaranta V, Juusela H, Gould VE, Virtanen I: Integrin distributions in renal cell carcinomas of various grades of malignancy. Am J Pathol 1992;141:1161-1171.
43. Terpe HJ, Tajrobehkar K, Gunthert U, Altmannsberger M: Expression of cell adhesion molecules alpha-2, alpha-5 and alpha-6 integrin, E-cadherin, N-CAM and CD-44 in renal cell carcinomas: An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1993;422:219-424.
44. Rabb H, Barroso-Vicens E, Adams R, Pow-Sang J, Ramirez G: Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol 1996;16:402-408.
45. Anastassiou G, Duensing S, Steinhoff G, Kirchner H, Ganser A, Atzpodien J: In vivo distribution of integrins in renal cell carcinoma: Integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastasis. Cancer Biother 1995;10:287-292.
46. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR, Schwartz RS, Mousa SA: Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997;36:408-428.
47. Muller JM, Chilian WM, Davis MJ: Integrin signaling transduces shear stress-dependent vasodilation of coronary arterioles. Circ Res 1997;80:320-326.